beraprost and Non-alcoholic-Fatty-Liver-Disease

beraprost has been researched along with Non-alcoholic-Fatty-Liver-Disease* in 1 studies

Other Studies

1 other study(ies) available for beraprost and Non-alcoholic-Fatty-Liver-Disease

Article	Year
Prostaglandin I FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2018, Volume: 32, Issue:5 Nonalcoholic steatohepatitis (NASH) is a hepatic manifestation of metabolic syndrome. Although the prostaglandin (PG)I Topics: Animals; Chemokine CCL2; Epoprostenol; Food, Formulated; Gene Expression Regulation; Hepatocytes; Kupffer Cells; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Receptors, Epoprostenol; Time Factors; Tumor Necrosis Factor-alpha	2018

Article

Year

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2018, Volume: 32, Issue:5

Nonalcoholic steatohepatitis (NASH) is a hepatic manifestation of metabolic syndrome. Although the prostaglandin (PG)I

Topics: Animals; Chemokine CCL2; Epoprostenol; Food, Formulated; Gene Expression Regulation; Hepatocytes; Kupffer Cells; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Receptors, Epoprostenol; Time Factors; Tumor Necrosis Factor-alpha

2018